Clinical trial · Observational
Genetic Investigation of Solid Tumors Cohort
NCT01005225CI-TRIAL-00014834completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this study is to obtain blood samples, solid tumor and/or benign hyperplasia samples to learn more about genetic differences that are linked to the formation of solid tumors.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Solid tumors
- description
- Participants 18 years of age or older who have been diagnosed with a solid tumor or benign hyperplasia that needs surgical removal will be included in this study.
Primary outcomes (1)
- measure
- Solid tumor biological insights
- timeFrame
- Study completion
- description
- Obtain blood samples, solid tumor and/or benign hyperplasia samples, and in some instances normal tissue in order to gain biological insights into cancer (solid tumors) through population genetics and genomics.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 18 years or older 2. Eligible to have their blood drawn 3. Be reliable, cooperative and willing to comply with all protocol-specified procedures 4. Able to understand and grant informed consent 5. Diagnosis of a solid tumor Exclusion Criteria: 1. Has a significant chronic medical condition which would potentially confound interpretation of the individual's phenotype. 2. Treatment with any investigational agents or devices within thirty days preceding enrollment in the study. 3. Been administered or taken any CNS sedatives or depressants in the 12 hours prior to informed consent process
References
Publications (0)
Data not yet available
No reference posted for this study.